The CTNNBIP1 (β-catenin interacting protein 1) antibody is a tool used to study the function of CTNNBIP1. a key regulatory protein in the Wnt/β-catenin signaling pathway. CTNNBIP1. also known as ICAT (inhibitor of β-catenin and TCF4), acts as a negative regulator by binding to β-catenin, disrupting its interaction with transcription factors like TCF/LEF, thereby suppressing Wnt target gene activation. This pathway is critical in embryonic development, tissue homeostasis, and cancer progression, where dysregulation often leads to tumorigenesis.
The CTNNBIP1 antibody is widely employed in research to detect and quantify CTNNBIP1 expression in cells or tissues, using techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). It helps elucidate the protein's role in modulating Wnt signaling, particularly in contexts like cancer (e.g., colorectal, hepatocellular carcinoma), stem cell regulation, and developmental biology. Studies using this antibody have highlighted its tumor-suppressive potential, as reduced CTNNBIP1 levels correlate with increased β-catenin activity and oncogenesis.
Commercial CTNNBIP1 antibodies are typically validated for specificity and sensitivity, often targeting epitopes within conserved regions of the protein. Researchers rely on these antibodies to explore therapeutic strategies targeting Wnt pathway aberrations, making CTNNBIP1 a focal point in both basic and translational studies.